Search Results

Displaying Results 1626-1650 of 2613 "'DNA'"

Oct 28, 2025, 01:55 ET Moving Walls Acquires Insightz Club to Lead the Out of Home Industry's AI Driven Transformation

taking a major leap forward—embedding AI and connected intelligence into the very core of our planning, activation, and measurement DNA. Moving Walls Science empowers marketers to go beyond data, applying true scientific precision to decode outcomes like impact, purchase,

More news about: Moving Walls


Oct 28, 2025, 00:57 ET Casio to Release G-SHOCK with Minimalist Metal Design and Even Better Fit

brick pattern on the dial are inspired by the design of the DW-5000C, the first-ever G-SHOCK. The GST-B1000D-1A reflects G-SHOCK DNA with its inset dial, which employs accent colors inspired by the first G-SHOCK: red symbolizing the passion to take on challenges, blue representing

More news about: CASIO COMPUTER CO., LTD


Oct 28, 2025, 00:11 ET Casio to Release G-SHOCK with Minimalist Metal Design and Even Better Fit

brick pattern on the dial are inspired by the design of the DW-5000C, the first-ever G-SHOCK. The GST-B1000D-1A reflects G-SHOCK DNA with its inset dial, which employs accent colors inspired by the first G-SHOCK: red symbolizing the passion to take on challenges, blue representing

More news about: CASIO COMPUTER CO., LTD


Oct 27, 2025, 16:10 ET Alexandria Real Estate Equities, Inc. Reports: 3Q25 and YTD 3Q25 Net Loss per Share - Diluted of $(1.38) and $(2.09), respectively; and 3Q25 and YTD 3Q25 FFO per Share - Diluted, as Adjusted, of $2.22 and $6.85, respectively

Alexandria®, Lighthouse Design® logo, Building the Future of Life-Changing Innovation®, That's What's in Our DNA®, Megacampus™, At the Vanguard and Heart of the Life Science Ecosystem™, Alexandria Center®, Alexandria Technology Square®,

More news about: Alexandria Real Estate Equities, Inc.


Oct 27, 2025, 08:45 ET Co-Diagnostics Signs Definitive Agreement with Arabian Eagle in the Kingdom of Saudi Arabia to Establish CoMira Diagnostics and Localize Co-Dx™ PCR Platform Across the Middle East

state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to

More news about: Co-Diagnostics


Oct 27, 2025, 08:05 ET INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025

biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancers, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting

More news about: INOVIO Pharmaceuticals, Inc.


Oct 27, 2025, 08:00 ET Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update

antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that

More news about: Acurx Pharmaceuticals, Inc.


Oct 27, 2025, 07:00 ET NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

proprietary super-precise TGEE programmable molecular "DNA scissors," which utilize two guide RNAs and an obligatory dimeric nuclease to achieve exceptional specificity. This approach enables safe and effective modification of a patient's own DNA, allowing precise gene deletion or gene replacement. TargetGene's

More news about: NLS Pharmaceutics Ltd.; Kadimastem Ltd.


Oct 27, 2025, 07:00 ET Mphasis Launches NeoIP™, a unified AI Platform for continuous Enterprise Transformation

decision-making and transformation. About Mphasis At Mphasis, engineering has been in our DNA since inception. Mphasis is an AI-led, platform-driven company with human-in-the-loop intelligence, helping global enterprises

More news about: Mphasis


Oct 27, 2025, 07:00 ET Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

NSCLC, associated with poor prognosis and osimertinib resistance, with the potent alpha-emitting isotope Ac-225, which induces irreversible double-strand DNA breaks. The preclinical data showed ATNM-400's differentiated potential as monotherapy, combination therapy with EGFR-inhibitors like osimertinib and

More news about: Actinium Pharmaceuticals, Inc.


Oct 24, 2025, 13:05 ET MVZ HPH führt ctDNA-Bluttest zur Krebsüberwachung in Europa ein, basierend auf der Haystack MRD®-Technologie von Quest Diagnostics®

Das MVZ HPH Institut für Pathologie und Hämatopathologie GmbH gibt die Verfügbarkeit von HPH MRD bekannt, einem neuen Bluttest für zirkulierende Tumor-DNA (ctDNA) zum Nachweis minimaler Resterkrankungen (MRD) bei Krebspatienten mit soliden Tumoren. Der HPH MRD-Test ist ein von HPH hergestellter In-House-Test,

More news about: Quest Diagnostics


Oct 24, 2025, 10:30 ET Palm Beach Motor Yachts Takes the Helm of the Iconic Wild Oats XI

ago and built on the same spirit of determination, precision, and innovation that has defined his racing success. "This is our DNA and a strategic direction shaped with the board of this great company to build brand awareness, strengthen marketing, elevate the customer experience,

More news about: Palm Beach Motor Yachts


Oct 24, 2025, 08:30 ET Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat

PSMA-resistant disease, a major unmet clinical need. Ac-225 delivers high-linear-energy-transfer alpha particles that induce irreparable double-strand DNA breaks, offering superior potency over beta emitters like Lutetium-177 (177Lu), and has a shorter tissue path length that may reduce off-target toxicity.

More news about: Actinium Pharmaceuticals, Inc.


Oct 23, 2025, 18:13 ET Bridgestone Launches RACING BATTLAX V03 Slick Motorcycle Tire

compound performances of both tires, the RACING BATTLAX V03 reduces lap times by 1.3% per lap2 – while still maintaining the typical Bridgestone DNA of high grip even after multiple laps. Newly Developed Rear 'SPRINT spec' for Maximum Performance in Sprint

More news about: Bridgestone Americas, Inc.


Oct 23, 2025, 17:45 ET Genomic Prediction Files Federal Lawsuit to Protect Trade Secrets and Intellectual Property and Enforce Its Rights

misappropriated GP's confidential research, trade secrets, and proprietary technology, including intellectual property related to embryonic DNA sequencing, amplification methods, and GP's LifeView® software platform. The lawsuit alleges that certain of the misappropriated information

More news about: Genomic Prediction


Oct 23, 2025, 17:31 ET Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight

that corrects errors occurring during DNA replication. Normally, the mismatch repair (MMR) mechanism detects and fixes mismatched base pairs or small insertions/deletions that arise during DNA synthesis or recombination. When this system loses functionality, DNA mutations accumulate, leading to genomic

More news about: DelveInsight Business Research, LLP


Oct 23, 2025, 16:58 ET CAGE Bio Announces Start of Double-Blind Vehicle-Controlled Clinical Trial of Novel Topical DNA Aptamer Therapy CGB-600 for Vitiligo Treatment

dermatological diseases, today announced the initiation of a randomized, double-blind, vehicle-controlled clinical trial evaluating its proprietary DNA Aptamer therapy, CGB-600, for the treatment of vitiligo.

More news about: CAGE Bio Inc.


Oct 23, 2025, 16:05 ET INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference

biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting

More news about: INOVIO Pharmaceuticals, Inc.


Oct 23, 2025, 13:55 ET Elite Aesthetics at the Forefront of the Mermaid Facial Trend

YORK, Oct. 23, 2025 /PRNewswire/ -- The skincare world is diving into the latest beauty phenomenon: Salmon DNA, and

More news about: Elite Aesthetics


Oct 23, 2025, 10:47 ET Ascent Hospitality Management Names Paul Damico Chief Executive Officer

the acquisition of additional brands that align with the company's growth strategy, vision, and values. "Hospitality is in my DNA and I am invigorated by the opportunity to work with our franchisees and the Ascent team to drive growth of Huddle House and Perkins, two beloved family

More news about: Ascent Hospitality Management


Oct 23, 2025, 10:00 ET Pillar Biosciences to Showcase NGS Research Insights at 2025 AMP Meeting

(Poster Number: TT072) Detecting Contamination in Cell-free DNA Sequencing Libraries using Germline Markers (Poster Number: IO040)

More news about: Pillar Biosciences, Inc.


Oct 23, 2025, 10:00 ET Generation Lab Raises $11M Seed Round as SystemAge™ Becomes World's Fastest-Growing Longevity Diagnostic

biological age—health of 19 organ systems/functions from intact primary blood results—that is based on discovery of the physiologic non-linear curve of DNA methylation aging. SystemAge greatly improves on alternatives that make predictions from man-made graphs after transforming data in a biologically arbitrary

More news about: Generation Lab


Oct 23, 2025, 09:00 ET Alloy Partners and Huntington Bank Launch New Venture Studio to Accelerate Innovation and Growth Across Banking

Parker, CEO of Alloy Partners. "This venture studio is not just about launching new businesses, it's about embedding innovation deep into the DNA of Huntington's growth story. Together, we're creating a repeatable engine to turn bold ideas into real-world outcomes." The collaboration

More news about: Alloy Partners


Oct 23, 2025, 08:33 ET BridGene Biosciences to Present Three Posters at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

single cysteine residue within the DNA-binding domain of PAX8, disrupting transcriptional activity and reducing the expression of downstream oncogenic targets including FGF18 and CCNA2. In biochemical and cellular assays, the compound showed dose-dependent inhibition of DNA binding in EMSA and selective suppression

More news about: BridGene Biosciences


Oct 23, 2025, 08:00 ET MACKAGE DEBUTS CORE 2025 CAMPAIGN FEATURING MATT BOMER AND STELLA MAXWELL

Los Angeles alongside a striking cast of animals: an owl, a falcon, an indigo snake, and two Dobermans. Each creature symbolizes a facet of Mackage's DNA, the owl for wisdom, the falcon for precision, the Dobermann for dedication, and the snake for protection. Together, they form a compelling visual metaphor

More news about: Mackage


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.